30,200 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by AdvisorShares Investments LLC

AdvisorShares Investments LLC acquired a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the 4th quarter, HoldingsChannel reports. The fund acquired 30,200 shares of the company’s stock, valued at approximately $930,000.

Other large investors have also added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its stake in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. NewEdge Advisors LLC boosted its stake in Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the period. Brown Brothers Harriman & Co. boosted its stake in Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the period. Founders Capital Management boosted its stake in Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 124.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after purchasing an additional 1,174 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of GMAB opened at $26.33 on Friday. The stock has a 50-day moving average price of $27.01 and a 200-day moving average price of $29.62. The company has a market cap of $16.42 billion, a PE ratio of 19.95, a price-to-earnings-growth ratio of 1.61 and a beta of 0.86. Genmab A/S Sponsored ADR has a 12-month low of $20.23 and a 12-month high of $35.43. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87.

Analysts Set New Price Targets

Several brokerages have commented on GMAB. Wolfe Research began coverage on Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price for the company. Guggenheim cut their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. HC Wainwright cut their target price on Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. Morgan Stanley began coverage on Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price for the company. Finally, Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.93.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.